Trial Profile
Observer Blind Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals Influenza Vaccine GSK576389A Administered to Adults Over 65 Years Previously Vaccinated With the Same Vaccine, Compared to Fluarix™
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 576389A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 13 Dec 2016 New trial record